医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

劳动节休市 04-30 16:00:00

1,107.753

+12.294

+1.12%

最高1,120.295	最低1,095.458	成交量7,245万
今开1,095.458	昨收1,095.458	日振幅2.27%
总市值0.00	流通市值0.00	总股本0.00
成交额9.40亿	换手率--	流通股本0.00
市净率1.403275	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":1107.7526,"timestamp":1777536491063,"preClose":1095.4581,"halted":0,"volume":72445310,"delay":0,"changeRate":0.011223,"floatShares":0,"shares":0,"eps":0,"marketStatus":"劳动节休市","change":12.294434,"latestTime":"04-30 16:00:00","open":1095.4581,"high":1120.2954,"low":1095.4581,"amount":939610281,"amplitude":0.022673,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"pbRate":1.403275,"peRate":12.64296,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593","defaultTab":"news","newsList":[{"id":"2631463758","title":"昊海生物科技(06826)：公司控股股东、实际控制人之一蒋伟因非本公司事项收到《取保候审决定书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2631463758","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631463758?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:38","pubTimestamp":1777552710,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技 发布公告，于近日收到控股股东、实际控制人之一蒋伟先生通知，因蒋伟先生涉嫌内幕交易案侦查所需，上海市公安局出具了《取保候审决定书》，决定对蒋伟先生取保候审，期限从2026年4月29日起算。具体内容详见公司于2025年12月24日在上海证券交易所网站披露的《上海昊海生物科技股份有限公司关于公司控股股东、实际控制人之一因非本公司事项收到<行政处罚决定书>的公告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1593","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631685178","title":"复星医药(600196.SH)控股子公司硝普钠注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631685178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631685178?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:27","pubTimestamp":1777537648,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司重庆药友制药有限责任公司就硝普钠注射液的药品注册申请获国家药品监督管理局批准。本次获批适应症为(1)高血压急症，如高血压危象、高血压脑病、恶性高血压、嗜铬细胞瘤手术前后阵发性高血压等的紧急降压，也可用于外科麻醉期间进行控制性降压;(2)急性心力衰竭，包括急性肺水肿，亦用于急性心肌梗死或瓣膜(二尖瓣或主动脉瓣)关闭不全时的急性心力衰竭。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK0175","BK0012","BK0060","BK0239","BK0096","BK1191","BK0183","BK1515","BK0028","BK0188","600196","BK0187","BK0196","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631506874","title":"甘蔗榨季结束，云南瑞丽边检站累计35万余吨甘蔗入境","url":"https://stock-news.laohu8.com/highlight/detail?id=2631506874","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631506874?lang=zh_cn&edition=full","pubTime":"2026-04-30 12:52","pubTimestamp":1777524720,"startTime":"0","endTime":"0","summary":"4月29日16时许，随着最后一车境外替代种植甘蔗从章凤口岸入境，预示着2025-2026甘蔗榨季正式结束，瑞丽出入境边防检查站也圆满完成了境外甘蔗返销入境保障工作。瑞丽边检民警对甘蔗车辆载运货物进行全面检查。瑞丽边检民警对入境货车司机进行信息核查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-04-30/doc-inhwhene7080839.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-30/doc-inhwhene7080839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1209","02135","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631577846","title":"港股异动 | 三生制药(01530)现涨超5% SSS68注射液三项适应症获中国IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631577846","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631577846?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:34","pubTimestamp":1777516454,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药现涨超5%，截至发稿，涨5.13%，报23.36港元，成交额3.02亿港元。值得一提的是，SSS68注射液是全球首个进入临床阶段的APRIL×BAFF双抗。值得注意的是，4月28日，三生制药自主研发的1类治疗用生物制品SSGJ-706注射液新药临床试验申请正式获得受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1593","HK0000165453.HKD","BK4588","01530","BK1161","IND","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631545160","title":"复星医药2026年一季报：扣非净利同比增长21.96% 将持续深化数字化与AI战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2631545160","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631545160?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:55","pubTimestamp":1777474529,"startTime":"0","endTime":"0","summary":"中国网财经4月29日讯昨日，复星医药(600196.SH；02196.HK)公布的“2026年第一季度业绩报告”显示，公司实现营业收入100.73亿元，同比增长6.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604293725107371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604293725107371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK1593","BK0183","AGIX","BK0187","BK0028","BK1515","600196","BK0096","02196","BK0239","BK0188","BK0060","AIPO","BK0012","ARTY","BK1191","CHAT","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630625300","title":"完美医疗(01830)：建议终止现有购股权计划及采纳2026年购股权计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2630625300","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630625300?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:27","pubTimestamp":1777382868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，完美医疗(01830)发布公告，于2026年4月28日，董事会建议采纳一份新购股权计划(2026年购股权计划)，并终止公司的现有购股权计划，以供公司股东批准。于2026年4月28日，董事会建议根据2026年购股权计划向欧阳江医生(其为公司主席、行政总裁、执行董事兼控股股东)有条件授出5000万份购股权。该等购股权将赋予承授人权利认购合共5000万股新股份，相当于本公布日期之已发行股份数目(不包括库存股)约3.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1215","01830","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630937793","title":"昊海生物科技(06826)4月28日斥资401.59万港元回购18.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630937793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630937793?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:09","pubTimestamp":1777370997,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，该公司于2026年4月28日斥资401.59万港元回购18.06万股股份，每股回购价格为21.92-22.4港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630237170","title":"昊海生物科技(06826)拟派发末期股息每股0.6元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630237170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630237170?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:32","pubTimestamp":1777368756,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，该公司拟派发末期股息每股0.6元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VIG","BK1593","06826","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153672630","title":"康哲药业与Pharmacosmos达成十五年协议 将独家生产供应Monofer与Cosmofer","url":"https://stock-news.laohu8.com/highlight/detail?id=1153672630","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153672630?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:18","pubTimestamp":1777288735,"startTime":"0","endTime":"0","summary":"康哲药业宣布与丹麦制药公司Pharmacosmos签署长期合作协议，后者将作为独家生产商，在未来十五年内持续为康哲药业供应铁剂产品Monofer和Cosmofer。\n此次合作进一步巩固了康哲药业在血液疾病治疗领域的供应链布局，确保核心产品Monofer（异麦芽糖铁1000）和Cosmofer（低分子右旋糖酐铁）的长期稳定生产和市场供应。Monofer作为新一代静脉铁剂，具有单次大剂量给药的便利性；Cosmofer则是成熟可靠的铁缺乏症治疗药物。\n长达十五年的供应协议体现出双方对产品市场前景的共同信心，也将助力康哲药业深化在贫血治疗领域的专业化布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","SG9999004220.SGD","00867","BK1593","IE00BVYPNP33.GBP","LU2488822045.USD","IE00BMCWC346.EUR","BK1191","IE00BYV24P56.USD","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999015978.USD","IE00BGHQDM52.EUR","SG9999015986.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165106210","title":"康哲药业签署Monofer®与Cosmofer®静脉铁剂独家商业化及供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1165106210","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165106210?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:04","pubTimestamp":1777287893,"startTime":"0","endTime":"0","summary":"康哲药业（867.HK/8a8.SG）宣布与合作伙伴达成一项重要协议，获得已上市原研静脉铁剂产品Monofer®及Cosmofer®的独家商业化权利与供应保障。该合作将显著增强公司在血液治疗领域的产品组合，为患者提供更全面的治疗方案。此次战略布局标志着康哲药业在专科用药市场拓展迈出关键一步，有望进一步提升其行业竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","SG9999015978.USD","LU2488822045.USD","BK1593","IE00BVYPNP33.GBP","IE00BMCWC346.EUR","IE00BYV24P56.USD","IE00BGHQDM52.EUR","SG9999015986.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","SG9999015952.SGD","SG9999004220.SGD","00867"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630436420","title":"昊海生物科技(06826)4月27日耗资约597.09万港元回购27.71万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630436420","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630436420?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:52","pubTimestamp":1777283548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)公布，2026年4月27日耗资约597.09万港元回购27.71万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","06826","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629844997","title":"昊海生物科技(06826)提名田敏为公司执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2629844997","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629844997?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:09","pubTimestamp":1777036180,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，公司于 2026年4月24日召开公司董事会会议审议通过，其中包括，提名田敏女士为公司执行董事候选人，以及分别提名陈少瑜先生、宋渊洋先生及许多奇女士为公司独立非执行董事候选人的议案。彼等候选人任期自公司股东于2025年年度股东会上批准之日起，至第六届董事会任期届满止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173915348","title":"康哲药业MG-K10季节性过敏性鼻炎新药上市申请获中国药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1173915348","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173915348?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:02","pubTimestamp":1776949373,"startTime":"0","endTime":"0","summary":"2026年4月23日，康哲药业（CMS）宣布其针对季节性过敏性鼻炎研发的新药MG-K10，已正式获得中国国家药品监督管理局（NMPA）的新药上市申请（NDA）受理。\n此次受理标志着MG-K10在中国的注册审批程序进入关键阶段。该药物若成功获批，将为国内季节性过敏性鼻炎患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNQ40.USD","IE00BYV24P56.USD","SG9999015978.USD","00867","LU2488822045.USD","IE00BMCWC346.EUR","SG9999004220.SGD","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","BK1593","BK1191","SG9999015986.USD","SG9999015945.SGD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629859954","title":"复锐医疗科技升级与Revance战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2629859954","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629859954?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:11","pubTimestamp":1776946260,"startTime":"0","endTime":"0","summary":"同时，公司将与Revance共同商讨合作机制及相关核心商业安排，实现在中国市场的长期可持续发展。复锐医疗科技表示，此次与Revance战略合作的全面升级，将加快达希斐在中国市场的商业化落地节奏，助力公司精准把握中国肉毒毒素市场的发展红利，夯实公司在注射填充领域的核心竞争力，推动这一增长引擎持续发力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4941952_ZH41952_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01696","BK1585","BK1100","BK1593"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2629836795","title":"时代天使(06699)：冯岱调任并获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2629836795","media":"智通财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629836795?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:57","pubTimestamp":1776945479,"startTime":"0","endTime":"0","summary":"智通财经APP讯，时代天使(06699)发布公告，非执行董事冯岱先生已调任并获委任为执行董事，自2026年4月23日起生效，并将继续担任董事会主席及董事会提名委员会主席。宋鑫先生已辞任董事，自2026年4月23日起生效，并将继续担任公司首席战略官。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1587","BK1593","BK1583","06699","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629833770","title":"康哲药业(00867)：1类新药MG-K10季节性过敏性鼻炎适应症中国上市许可申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2629833770","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629833770?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:14","pubTimestamp":1776942858,"startTime":"0","endTime":"0","summary":"MG-K10已于一项成人中重度季节性过敏性鼻炎的多中心、随机、双盲、安慰剂对照的III期临床研究中达到方案设计的主要研究终点。MG-K10作为以IL-4Rα为靶点的生物制剂，可从源头阻断2型炎症通路。MG-K10季节性过敏性鼻炎适应症上市申请获NMPA受理，是本集团眼科业务公司康哲维盛将治疗领域从眼科拓展至耳鼻喉科的重要跨越，亦是本集团在2型炎症性疾病领域研发进程中的又一重要里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BVYPNQ40.USD","IPOS","IE00BYV24P56.USD","BK1191","00867","BK4123","MG","BK1593","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","IE00B7SZL793.SGD","SG9999015945.SGD","SG9999015978.USD","IE0031619046.USD","IE00BVYPNP33.GBP","IE00B66KJ199.SGD","LU2488822045.USD","IE00B19Z4B17.USD","SG9999015986.USD","SG9999004220.SGD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178655867","title":"康哲药业1类创新药Mg-K10季节性过敏性鼻炎适应症在华上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1178655867","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178655867?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:10","pubTimestamp":1776942616,"startTime":"0","endTime":"0","summary":"康哲药业宣布，其1类创新药Mg-K10用于治疗季节性过敏性鼻炎的上市申请已获中国国家药品监督管理局正式受理。\n该药物作为公司创新管线的重要组成，标志着康哲药业在过敏治疗领域取得关键进展。此次受理将加速Mg-K10在中国市场的商业化进程，为季节性过敏性鼻炎患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQDM52.EUR","BK1593","IE00BMCWC346.EUR","IE00BYV24P56.USD","SG9999015978.USD","SG9999015986.USD","IE00BVYPNQ40.USD","BK1191","00867","LU2488822045.USD","IE00BVYPNP33.GBP","SG9999004220.SGD","SG9999015945.SGD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","OILU","LU2242644610.SGD","BK1583","ERX","LU2488822045.USD","USL","GUSH","BK1161","OILT","01801","USOI","LU1969619763.USD","HK0000165453.HKD","VDE","BK4585","09995","DBO","DBC","LU2328871848.SGD","DBE","06978","BK1574","UGA","DIG","03692","LU2097828631.EUR","LU0455707207.USD","01530","BK1593","BK4570","159992","DRLL","LU0502904849.HKD","BWET","USE","OIH","BK1589","IEO","LU2097828557.USD","PXJ","BK1191","BNO","LU2097828474.EUR","DUG","OILK","IXC","LU2097828714.EUR","DRIP","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629043481","title":"复锐医疗科技(01696)：控股股东层面重组完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2629043481","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629043481?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:31","pubTimestamp":1776857518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复锐医疗科技(01696)发布公告，有关控股股东层面建议重组，根据重组公告披露，复星医药间接全资附属公司能悦与美中互利分别签订协议，同意转让其持有的全部公司股份权益(合计约占截至本公告日公司全部发行股份的71.42%)予另一家复星医药间接全资附属公司FPI。于2026年4月22日，公司董事会收到复星医药通知，根据其协议条款，此次重组已经完成。因此，截至本公告日，复星医药间接全资附属公司FPI持有3.345亿股公司股份，复星医药间接持有公司的股权比例保持不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1585","BK1593","01696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629489260","title":"完美医疗(01830)：欧阳江、欧阳慧及苏显龙不再担任薪酬委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2629489260","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629489260?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:11","pubTimestamp":1776856277,"startTime":"0","endTime":"0","summary":"智通财经APP讯，完美医疗(01830)发布公告，本公司执行董事欧阳江医生、欧阳慧女士及苏显龙先生不再为本公司薪酬委员会的成员，自2026年4月23日生效。在前述变动以后，薪酬委员会的成员由季志雄先生(主席)、徐慧敏女士、曹依萍女士及戚世昌先生组成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1215","01830"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}